Cargando…
Conversion therapy for massive hepatocellular carcinoma: A case report and literature review
KEY CLINICAL MESSAGE: For potentially resectable HCC, a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used. ABSTRACT: Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. The best treatment for HCC is radical...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264960/ https://www.ncbi.nlm.nih.gov/pubmed/37323266 http://dx.doi.org/10.1002/ccr3.7533 |
_version_ | 1785058436360175616 |
---|---|
author | Zhou, Zheyu Xu, Xiaoliang Sun, Meiling Liu, Yang Liu, Qiaoyu Chen, Chaobo Yin, Yin |
author_facet | Zhou, Zheyu Xu, Xiaoliang Sun, Meiling Liu, Yang Liu, Qiaoyu Chen, Chaobo Yin, Yin |
author_sort | Zhou, Zheyu |
collection | PubMed |
description | KEY CLINICAL MESSAGE: For potentially resectable HCC, a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used. ABSTRACT: Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. The best treatment for HCC is radical surgical resection, but 70%–80% of patients are ineligible for surgery. Although conversion therapy is an established treatment strategy for various solid tumors, there is no uniform protocol for treating HCC. In this case, we present a 69‐year‐old male patient diagnosed with massive HCC with Barcelona clinical liver cancer (BCLC) stage B. Because of the insufficient volume of the future liver remnant, we believed radical surgical resection was temporarily impossible. Therefore, the patient received conversion therapy, including four cycles of transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC‐Folfox), lenvatinib (8 mg orally once a day), and tislelizumab (an anti‐PD‐1 antibody, 200 mg intravenously once every 3 weeks). Fortunately, the patient achieved a good treatment response (smaller lesions and improved liver function) and underwent radical surgery finally. There was no clinical evidence of recurrence at 6 months of follow‐up. For potentially resectable HCC, this case reveals that a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used. |
format | Online Article Text |
id | pubmed-10264960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102649602023-06-15 Conversion therapy for massive hepatocellular carcinoma: A case report and literature review Zhou, Zheyu Xu, Xiaoliang Sun, Meiling Liu, Yang Liu, Qiaoyu Chen, Chaobo Yin, Yin Clin Case Rep Case Report KEY CLINICAL MESSAGE: For potentially resectable HCC, a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used. ABSTRACT: Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. The best treatment for HCC is radical surgical resection, but 70%–80% of patients are ineligible for surgery. Although conversion therapy is an established treatment strategy for various solid tumors, there is no uniform protocol for treating HCC. In this case, we present a 69‐year‐old male patient diagnosed with massive HCC with Barcelona clinical liver cancer (BCLC) stage B. Because of the insufficient volume of the future liver remnant, we believed radical surgical resection was temporarily impossible. Therefore, the patient received conversion therapy, including four cycles of transcatheter arterial embolization (TAE) and hepatic arterial infusion chemotherapy (HAIC‐Folfox), lenvatinib (8 mg orally once a day), and tislelizumab (an anti‐PD‐1 antibody, 200 mg intravenously once every 3 weeks). Fortunately, the patient achieved a good treatment response (smaller lesions and improved liver function) and underwent radical surgery finally. There was no clinical evidence of recurrence at 6 months of follow‐up. For potentially resectable HCC, this case reveals that a more aggressive conversion therapy strategy (high‐intensity combined with multiple treatment modalities) can be used. John Wiley and Sons Inc. 2023-06-13 /pmc/articles/PMC10264960/ /pubmed/37323266 http://dx.doi.org/10.1002/ccr3.7533 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Report Zhou, Zheyu Xu, Xiaoliang Sun, Meiling Liu, Yang Liu, Qiaoyu Chen, Chaobo Yin, Yin Conversion therapy for massive hepatocellular carcinoma: A case report and literature review |
title | Conversion therapy for massive hepatocellular carcinoma: A case report and literature review |
title_full | Conversion therapy for massive hepatocellular carcinoma: A case report and literature review |
title_fullStr | Conversion therapy for massive hepatocellular carcinoma: A case report and literature review |
title_full_unstemmed | Conversion therapy for massive hepatocellular carcinoma: A case report and literature review |
title_short | Conversion therapy for massive hepatocellular carcinoma: A case report and literature review |
title_sort | conversion therapy for massive hepatocellular carcinoma: a case report and literature review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264960/ https://www.ncbi.nlm.nih.gov/pubmed/37323266 http://dx.doi.org/10.1002/ccr3.7533 |
work_keys_str_mv | AT zhouzheyu conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview AT xuxiaoliang conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview AT sunmeiling conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview AT liuyang conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview AT liuqiaoyu conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview AT chenchaobo conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview AT yinyin conversiontherapyformassivehepatocellularcarcinomaacasereportandliteraturereview |